Authors:
Guichard, S
Montazeri, A
Chatelut, E
Hennebelle, I
Bugat, R
Canal, P
Citation: S. Guichard et al., Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: Pharmacokinetic and pharmacodynamic evaluation, CLIN CANC R, 7(10), 2001, pp. 3222-3228
Authors:
Patoux, A
Bleyzac, N
Boddy, AV
Doz, F
Rubie, H
Bastian, G
Maire, P
Canal, P
Chatelut, E
Citation: A. Patoux et al., Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children, EUR J CL PH, 57(4), 2001, pp. 297-303
Authors:
Chatelut, E
Pivot, X
Otto, J
Chevreau, C
Thyss, A
Renee, N
Milano, G
Canal, P
Citation: E. Chatelut et al., A limited sampling strategy for determining carboplatin AUC and monitoringdrug dosage, EUR J CANC, 36(2), 2000, pp. 264-269
Authors:
Hennebelle, I
Terret, C
Chatelut, E
Bugat, R
Canal, P
Guichard, S
Citation: I. Hennebelle et al., Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitra-phenylacetate converting carboxylesterase activity, ANTI-CANC D, 11(6), 2000, pp. 465-470
Authors:
Montazeri, A
Boucaud, M
Lokiec, F
Pinguet, F
Culine, S
Deporte-Fety, R
Albin, N
Laguerre, B
Goupil, A
Bugat, R
Canal, P
Chatelut, E
Citation: A. Montazeri et al., Population pharmacokinetics of topotecan: intraindividual variability in total drug, CANC CHEMOT, 46(5), 2000, pp. 375-381
Authors:
Guimbaud, R
Guichard, S
Dusseau, C
Bertrand, V
Aparicio, T
Lochon, I
Chatelut, E
Couturier, D
Bugat, R
Chaussade, S
Canal, P
Citation: R. Guimbaud et al., Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans, CANC CHEMOT, 45(6), 2000, pp. 477-482
Authors:
Simeon, N
Chatelut, E
Canal, P
Nertz, M
Couderc, F
Citation: N. Simeon et al., Anthracycline analysis by capillary electrophoresis - Application to the analysis of daunorubicine in Kaposi sarcoma tumor, J CHROMAT A, 853(1-2), 1999, pp. 449-454
Authors:
Tranchand, B
Amsellem, C
Chatelut, E
Freyer, G
Iliadis, A
Ligneau, B
Trillet-Lenoir, V
Canal, P
Lochon, I
Ardiet, CJ
Citation: B. Tranchand et al., A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients, CANC CHEMOT, 43(4), 1999, pp. 316-322
Authors:
Gladieff, L
Chatelut, E
Gaspard, MH
Skaf, R
de Forni, M
Mihura, J
Canal, P
Bugat, R
Citation: L. Gladieff et al., Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study, B CANCER, 86(7-8), 1999, pp. 673-677
Authors:
Guichard, S
Terret, C
Hennebelle, I
Lochon, I
Chevreau, P
Fretigny, E
Selves, J
Chatelut, E
Bugat, R
Canal, P
Citation: S. Guichard et al., CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues, BR J CANC, 80(3-4), 1999, pp. 364-370
Authors:
Perdaems, N
Bachaud, JM
Rouzaud, P
Murris-Espin, M
Hermant, C
Mihura, J
Lochon, I
Houin, G
Canal, P
Chatelut, E
Citation: N. Perdaems et al., Relation between unbound plasma concentrations and toxicity in a prolongedoral etoposide schedule, EUR J CL PH, 54(9-10), 1998, pp. 677-683